Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
32583-1-PBS targets ZSCAN1 in WB, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag37955 Product name: Recombinant human ZSCAN1 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 261-400 aa of NM_182572 Sequence: HQPSLKHTKGGTQEAVAGISVVPRGPRGGRPFQCADCGMVFTWVTHFIEHQKTHREEGPFPCPECGKVFLHNSVLTEHGKIHLLEPPRKKAPRSKGPRESVPPRDGAQGPVAPRSPKRPFQCSVCGKAFPWMVHLIDHQK 相同性解析による交差性が予測される生物種 |
| Full Name | zinc finger and SCAN domain containing 1 |
| Calculated molecular weight | 408 aa, 45 kDa |
| Observed molecular weight | 45 kDa |
| GenBank accession number | NM_182572 |
| Gene Symbol | ZSCAN1 |
| Gene ID (NCBI) | 284312 |
| RRID | AB_3742661 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity Purification |
| UNIPROT ID | Q8NBB4 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
ZSCAN1 is a transcription factor containing a zinc finger domain and a SCAN domain. ZSCAN1 has been implicated in diverse biological processes. It has been shown to act as a stemness-related tumor suppressor and transcriptional repressor in breast cancer, targeting TAZ to influence cancer progression. Additionally, ZSCAN1 is involved in early embryonic development, where it helps regulate the expression of genes necessary for proper embryogenesis. It also plays a role in the immune response, with anti-ZSCAN1 autoantibodies being identified as potential diagnostic markers for certain syndromes like ROHHAD (PMID: 38339072). According to Human Protein Atlas database, ZSCAN1 is mainly expressed in brain, pituitary gland and testis tissue.
